- Home
- NEXM vs INO Comparison
NEXM vs INO Comparison
Compare NEXM & INO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NEXM | INO |
|---|---|---|
| Founded | N/A | 1979 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 145.5M | 118.9M |
| IPO Year | N/A | 1999 |
Fundamental Metrics
Financial Performance| Metric | NEXM | INO |
|---|---|---|
| Price | $3.26 | $1.75 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 67.9K | ★ 804.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 35.14 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $42,220,086.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $23,060.18 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 19.37 |
| 52 Week Low | $3.06 | $1.30 |
| 52 Week High | $6.75 | $2.86 |
Technical Indicators
Market Signals| Indicator | NEXM | INO |
|---|---|---|
| Relative Strength Index (RSI) | 42.23 | 52.08 |
| Support Level | $3.37 | $1.72 |
| Resistance Level | $4.03 | $1.78 |
| Average True Range (ATR) | 0.22 | 0.09 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 18.69 | 28.75 |
Price Performance
Historical ComparisonAbout NEXM NexMetals Mining Corp.
NexMetals Mining Corp is a mineral exploration and development company focused on discovering and advancing high-quality copper-nickel-cobalt-platinum element metals (Cu- Cu-Ni-Co-PGE) resources. The group prioritizes projects in stable, mining-friendly jurisdictions with supportive foreign investment and rule-of-law standards. Its projects are Botswana and Canada.
About INO Inovio Pharmaceuticals Inc.
Inovio Pharmaceuticals Inc is a United States-based biotechnology company. The company is focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.